158 related articles for article (PubMed ID: 37345121)
21. Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.
Mota JM; Armstrong AJ; Larson SM; Fox JJ; Morris MJ
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):522-530. PubMed ID: 31036925
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.
Al-Ezzi EM; Alqaisi HA; Iafolla MAJ; Wang L; Sridhar SS; Sacher AG; Fallah-Rad N; Jiang DM; Watson GA; Catton CN; Warde PR; Hamilton RJ; Fleshner NE; Zlotta AR; Hansen AR
Cancer Med; 2021 Sep; 10(17):5775-5782. PubMed ID: 34254464
[TBL] [Abstract][Full Text] [Related]
23. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
Nome R; Hernes E; Bogsrud TV; Bjøro T; Fosså SD
Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952
[TBL] [Abstract][Full Text] [Related]
24. Baseline
García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
[TBL] [Abstract][Full Text] [Related]
25. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer.
Wong WW; Anderson EM; Mohammadi H; Daniels TB; Schild SE; Keole SR; Choo CR; Tzou KS; Bryce AH; Ho TH; Quevedo FJ; Vora SA
Clin Genitourin Cancer; 2017 Dec; 15(6):e969-e975. PubMed ID: 28545997
[TBL] [Abstract][Full Text] [Related]
26. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Bauckneht M; Rebuzzi SE; Signori A; Frantellizzi V; Murianni V; Lodi Rizzini E; Mascia M; Lavelli V; Donegani MI; Ponzano M; Gaudiano A; Stazza ML; Licari M; Cavallini L; Laghi V; Cindolo L; Maggi M; Sciarra A; Mammucci P; Sambuceti G; Costa RP; Spanu A; Rubini G; Monari F; De Vincentis G; Fornarini G
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1063-1074. PubMed ID: 34486070
[TBL] [Abstract][Full Text] [Related]
27. Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer.
Haupt F; Berding G; Namazian A; Wilke F; Böker A; Merseburger A; Geworski L; Kuczyk MA; Bengel FM; Peters I
Adv Ther; 2017 Apr; 34(4):986-994. PubMed ID: 28265811
[TBL] [Abstract][Full Text] [Related]
28. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullén A
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3325-3334. PubMed ID: 33686456
[TBL] [Abstract][Full Text] [Related]
29. Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.
Reza M; Jones R; Aspegren J; Massard C; Mattila L; Mustonen M; Wollmer P; Trägårdh E; Bondesson E; Edenbrandt L; Fizazi K; Bjartell A
Eur Urol Focus; 2016 Dec; 2(5):547-552. PubMed ID: 28723521
[TBL] [Abstract][Full Text] [Related]
30. Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
Yang HC; Chang LW; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Chen CC; Wang SC; Lin CY; Cheng CL; Ou YC; Chiu KY; Hung SC
Anticancer Res; 2023 Apr; 43(4):1809-1816. PubMed ID: 36974814
[TBL] [Abstract][Full Text] [Related]
31. Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases.
Hirano H; Nagata M; Nagaya N; Nakamura S; Ashizawa T; Lu Y; Kawano H; Kitamura K; Sakamoto Y; Fujita K; Isobe H; Tsujimura A; Muto S; Horie S
Sci Rep; 2023 May; 13(1):8704. PubMed ID: 37248346
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study.
Matsumoto T; Hori Y; Shiota M; Blas L; Nakamura M; Seki N; Kuroiwa K; Yokomizo A; Morokuma F; Kiyoshima K; Eto M
Int J Urol; 2023 Feb; 30(2):139-146. PubMed ID: 36305673
[TBL] [Abstract][Full Text] [Related]
33. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
Poulsen MH; Rasmussen J; Edenbrandt L; Høilund-Carlsen PF; Gerke O; Johansen A; Lund L
BJU Int; 2016 May; 117(5):748-53. PubMed ID: 25906907
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
Armstrong AJ; Kaboteh R; Carducci MA; Damber JE; Stadler WM; Hansen M; Edenbrandt L; Forsberg G; Nordle Ö; Pili R; Morris MJ
Urol Oncol; 2014 Nov; 32(8):1308-16. PubMed ID: 25240761
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen flare induced by
Castello A; Macapinlac HA; Lopci E; Santos EB
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
[TBL] [Abstract][Full Text] [Related]
36. Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital.
Nakashima K; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Matsuo S; Mizokami A
Anticancer Res; 2019 May; 39(5):2607-2614. PubMed ID: 31092459
[TBL] [Abstract][Full Text] [Related]
37. Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer.
Miyoshi Y; Sakamoto S; Kawahara T; Uemura K; Yokomizo Y; Uemura H
Urol Int; 2019; 103(3):279-284. PubMed ID: 31461725
[TBL] [Abstract][Full Text] [Related]
38. Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy.
Lu HH; Chiu NT; Tsai MH
Ann Nucl Med; 2024 Apr; ():. PubMed ID: 38647876
[TBL] [Abstract][Full Text] [Related]
39. The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
Ali A; Hoyle AP; Parker CC; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Attard G; Parmar MKB; Sydes MR; James ND; Clarke NW;
Eur Urol Oncol; 2020 Aug; 3(4):412-419. PubMed ID: 32591246
[TBL] [Abstract][Full Text] [Related]
40. Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy.
Wenter V; Herlemann A; Fendler WP; Ilhan H; Tirichter N; Bartenstein P; Stief CG; la Fougère C; Albert NL; Rominger A; Gratzke C
Oncotarget; 2017 Jul; 8(27):44131-44140. PubMed ID: 28484088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
